Abstract
Conventional treatment of moderate-severe ulcerative colitis (UC) has resulted in only a limited therapeutic benefit. Advancing knowledge of UC pathogenesis and recent advances in biotechnology have led to the development of biological agents that selectively target individual inflammatory pathways. In particular, the role of tumor necrosis factor alpha (TNF-α) in UC pathogenesis has been clarified by serological and immunohistochemical studies in humans and by experimental models. Clinical efficacy of anti-TNF-α therapy with infliximab has been assessed in two large controlled trials, showing a good compromise between therapeutic gain and safety. The aim of this review is to provide an insight into the role of TNF-α and anti-TNF-α therapy in patients with UC and diverticular disease associated colitis.
Keywords: Biological therapy, ulcerative colitis, diverticular disease associated colitis
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Tumor Necrosis Factor Alpha in Ulcerative Colitis and Diverticular Disease Associated Colitis
Volume: 7 Issue: 3
Author(s): C. Hassan, A. Zullo, V. De Francesco, S. M.A. Campo, S. Morini, C. Panella and E. Ierardi
Affiliation:
Keywords: Biological therapy, ulcerative colitis, diverticular disease associated colitis
Abstract: Conventional treatment of moderate-severe ulcerative colitis (UC) has resulted in only a limited therapeutic benefit. Advancing knowledge of UC pathogenesis and recent advances in biotechnology have led to the development of biological agents that selectively target individual inflammatory pathways. In particular, the role of tumor necrosis factor alpha (TNF-α) in UC pathogenesis has been clarified by serological and immunohistochemical studies in humans and by experimental models. Clinical efficacy of anti-TNF-α therapy with infliximab has been assessed in two large controlled trials, showing a good compromise between therapeutic gain and safety. The aim of this review is to provide an insight into the role of TNF-α and anti-TNF-α therapy in patients with UC and diverticular disease associated colitis.
Export Options
About this article
Cite this article as:
Hassan C., Zullo A., De Francesco V., Campo M.A. S., Morini S., Panella C. and Ierardi E., Tumor Necrosis Factor Alpha in Ulcerative Colitis and Diverticular Disease Associated Colitis, Endocrine, Metabolic & Immune Disorders - Drug Targets 2007; 7 (3) . https://dx.doi.org/10.2174/187153007781662530
DOI https://dx.doi.org/10.2174/187153007781662530 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gold and Silver Nanoparticles for Applications in Theranostics
Current Topics in Medicinal Chemistry Is it Necessary to Calculate Young’s Modulus in AFM Nanoindentation Experiments Regarding Biological Samples?
Micro and Nanosystems Recent Progress in Research on Ribosome Inactivating Proteins
Current Protein & Peptide Science Phytochemicals from Peanut (<i>Arachis hypogaea</i> L.) Skin Extract with Potential for Pharmacological Activity
Current Bioactive Compounds Advances in Characterization of Human Sirtuin Isoforms: Chemistries, Targets and Therapeutic Applications
Current Medicinal Chemistry Effects of Elicitors, Viticultural Factors, and Enological Practices on Resveratrol and Stilbenes in Grapevine and Wine
Mini-Reviews in Medicinal Chemistry Metal Complexes of Natural Product Like-compounds with Antitumor Activity
Anti-Cancer Agents in Medicinal Chemistry Multi-scale modularity and motif distributional effect in metabolic networks
Current Protein & Peptide Science Computer-Aided Drug Design for AMP-Activated Protein Kinase Activators
Current Computer-Aided Drug Design Cyclopamine, a Naturally Occurring Alkaloid, and Its Analogues May Find Wide Applications in Cancer Therapy
Current Topics in Medicinal Chemistry Epidemiology, Evolution, Transmission, and Therapeutics of COVID-19 Outbreak: An Update on the Status
Coronaviruses Current Applications of Artificial Neural Networks in Biochemistry with Emphasis on Cancer Research
Current Biochemical Engineering (Discontinued) Pharmacological Potential of Tetrahydrofurano/Pyrano Quinoline and Benzo[b]furoindolyl Derivatives in Acute Inflammation, Pain and Oxidative Stress
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Guanylate Cyclase C: A Current Hot Target, from Physiology to Pathology
Current Medicinal Chemistry Current Perspectives of Healthy Mitochondrial Function for Healthy Neurons
Current Drug Targets Synergistic Extraction of Zn2+ from Aqueous Buffer Medium of Chloride Ions into 1- Phenyl -3- Methyl -4- Trichloro Acetyl Pyrazolone - 5 in Benzene and Hexane
Recent Patents on Materials Science New Developments in Anti-Angiogenic Therapy of Cancer, Review and Update
Anti-Cancer Agents in Medicinal Chemistry Extraction, Structure and Bioactivities of the Polysaccharides from Fructus corni
Recent Patents on Food, Nutrition & Agriculture Nanoparticle-Based Technologies for the Detection of Food Antioxidants
Current Analytical Chemistry Design, Synthesis and Evaluation of Hybrid 2-Heteroaryl Benzimidazole- Chalcone Derivatives as Anticancer Agents
Letters in Organic Chemistry